Pacific Biosciences Of California (PACB) Cash from Operations Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.86 Bn | 176.56 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.65 Bn | 125.78 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.34 Bn | 66.89 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.65 Bn | 1.29 Bn | -84.38% |
| 6 | GE HealthCare Technologies | 28.35 Bn | 26.07 Bn | 1.98 Bn | 16.00% |
| 7 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 185.96% |
| 8 | Smith & Nephew | 26.90 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 122.43% |
| 10 | Pacific Biosciences Of California | 417.44 Mn | 141.48 Mn | 12.84 Mn | -1.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.44% |
| Dec 31, 2025 | 37.78% |
| Sep 30, 2025 | 58.85% |
| Jun 30, 2025 | 45.86% |
| Mar 31, 2025 | 41.79% |
| Dec 31, 2024 | 46.75% |
| Sep 30, 2024 | 30.25% |
| Jun 30, 2024 | -30.00% |
| Mar 31, 2024 | 20.07% |
| Dec 31, 2023 | 4.96% |
| Sep 30, 2023 | -3.37% |
| Jun 30, 2023 | 31.08% |
| Mar 31, 2023 | -19.82% |
| Dec 31, 2022 | -91.01% |
| Jun 30, 2022 | -285.46% |
| Mar 31, 2022 | -242.06% |
| Dec 31, 2021 | -122.31% |
| Jun 30, 2021 | 33.95% |
| Mar 31, 2021 | -130.66% |
| Dec 31, 2020 | 21.55% |